Table 2.
Overview of immunotherapy in metastatic collecting duct carcinoma.
| Reference | n mCDC patients | Treatment | Treatment-line | Responders |
|---|---|---|---|---|
| Watanabe et al. (2019) 13 | 1 | nivolumab + ipilimumab | first-line | 1 (CR) |
| Fuu et al. (2022) 14 | 1 | nivolumab + ipilimumab | first-line | 1 (CR) |
| Koshkin et al. (2018) 15 | 4 | nivolumab | first-line or subsequent lines* | 1 (PR) |
| Yasuoka et al. (2018) 7 | 1 | nivolumab | fourth-line** | 1 (PR) |
| Danno et al. (2021) 16 | 2 | nivolumab + ipilimumab | first-line | 1 (PR) |
| Vogelzang et al. (2020) 17 | 1 | nivolumab | second-line | 1 (PR) |
| Tykodi et al. (2022) 18 | 2 | nivolumab + ipilimumab | first-line | 0 |
| Mizutani et al. (2017) 6 | 1 | nivolumab | fourth-line*** | 1 (CR lung, SD lymph node) |
| Present case series | 4 | nivolumab | second-line (after cabozantinib) | 1 (PR) |
CR, complete response; mCDC, metastatic collecting duct carcinoma; PR, partial response.
*
previous treatment lines could include chemotherapy, TKIs or mTOR inhibitor.
**
patient pre-treated with cisplatin plus gemcitabine (first-line treatment), axitinib (second-line treatment), carboplatin plus paclitaxel (third-line treatment).
***
patient pre-treated with cisplatin plus gemcitabine (first-line treatment), paclitaxel plus gemcitabine (second-line treatment), temsirolimus (third-line treatment).